Nemus Bioscience, Inc.
SKYE US83086J2006
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Annual Performance 1
| 2024 | 2025 |
|---|---|
| -78% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Schwab Andrew J. O |
3.42 USD |
6,470 Sold |
22,127 USD |
21/08/2025 | 22/08/2025 |
| Schwab Andrew J. O |
3.42 USD |
163,979 Sold |
560,808 USD |
21/08/2025 | 22/08/2025 |
| Schwab Andrew J. O |
3.57 USD |
58,642 Sold |
209,352 USD |
21/08/2025 | 21/08/2025 |
| Schwab Andrew J. O |
3.57 USD |
2,314 Sold |
8,261 USD |
21/08/2025 | 21/08/2025 |
| Diep Tuan Tu BDM |
4.99 USD |
19,489 Sold |
97,250 USD |
15/11/2024 | 18/11/2024 |
| Arsenault Kaitlyn CFO |
4.99 USD |
43,206 Sold |
215,598 USD |
15/11/2024 | 18/11/2024 |
| Diep Tuan Tu BDM |
4.99 USD |
19,489 Sold |
97,250 USD |
15/11/2024 | 18/11/2024 |
| Dhillon Punit CEO |
4.99 USD |
82,546 Sold |
411,905 USD |
15/11/2024 | 18/11/2024 |
| Grayson Paul A. |
4.99 USD |
86,244 Sold |
430,358 USD |
15/11/2024 | 18/11/2024 |
| Grayson Paul A. |
4.99 USD |
86,244 Sold |
430,358 USD |
15/11/2024 | 18/11/2024 |